Model-based dose finding under model uncertainty using general parametric models

Statistics in Medicine

Volumn 33, Issue 10, 2014, Pages 1646-1661

  Pinheiro, José ^a   Bornkamp, Björn ^b   Glimm, Ekkehard ^b   Bretz, Frank ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Binary data; Count data; Dose response; MCP Mod; Parametric; Time to event data

Indexed keywords

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; GENERAL PARAMETRIC MODEL; MULTIPLE COMPARISON PROCEDURES AND MODELING APPROACH; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDY DESIGN; UNCERTAINTY; UNIVARIATE ANALYSIS; COMPUTER SIMULATION; HUMAN; NEURODEGENERATIVE DISEASES; PROCEDURES;

CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, STATISTICAL; NEURODEGENERATIVE DISEASES; SOFTWARE; UNCERTAINTY;

EID: 84898015197     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6052     Document Type: Article

References (40)

1. Lin D, Shkedy Z, Yekutieli D, Amaratunga D, Bijnens L. Modeling Dose-response Microarray Data in Early Drug Development Experiments With R. Spinger: New York, 2012.
2. Bretz F, Hothorn L. Statistical analysis of monotone or non-monotone dose-response data from in-vitro toxicological assays. Alternatives to Laboratory Animals 2003; 31 Supplement 1: 81-96.
3. Hoel D, Portier C. Nonlinearity of dose-response functions for carcinogenicity. Enrironmental Health Perspectives 1994; 102 Supplement 1: 109-113.
4. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to Phase I cancer trials. Statistics in Medicine 2008; 27: 2420-2439.
5. Hsu CH. Evaluating potential benefits of dose-exposure-response modeling for dose finding. Pharmaceutical Statistics 2009; 8: 203-215.
6. Ruberg SJ. Dose response studies. I. Some design considerations. Journal of Biopharmaceutical Statistics 1995; 5(1):1-14.
7. Ruberg SJ. Dose response studies. II. Analysis and interpretation. Journal of Biopharmaceutical Statistics 1995; 5(1):15-42.
8. ICH. ICH Topic E4: Dose-response information to support drug registration, E4 1994.
9. Ting N. Dose Finding in Drug Development. Spinger: New York, 2006.
10. Chevret S. Statistical Methods for Dose Finding Experiments. Wiley: Chichester, UK, 2006.
11. Krishna R. Dose Optimization in Drug Development. Informa Healthcare: New York, 2006.
12. Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu CH, König F, Krams M, Liu Q, Neuenschwander B, Parke T, Pinheiro JC, Roy A, Sax R, Shen F. Innovative approaches for designing and analyzing adaptive dose-ranging trials. Journal of Biopharmaceutical Statistics 2007; 17: 965-995.
13. Pinheiro J, Sax F, Bornkamp ZAB, Bretz F, Chuang-Stein C, Dragalin V, Fardipour P, Gallo P, Gillespie W, Hsu C, Padmanabhan FMS, Patel N, Perevozskaya I, Roy A, Sanil A, Smith J. Adaptive and model-based dose-ranging trials: quantitative evaluation and recommendations. White paper of the PhRMA working group on adaptive dose-ranging studies (with discussion). Statistics in Biopharmaceutical Research 2010; 2: 435-454.
14. Pinheiro JC, Bretz F, Branson M. Analysis of dose-response studies-modeling approaches. In Dose Finding in Drug Development, Ting N (ed.). Springer: New York, 2006; 146-171.
15. Thomas N. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose designs. Journal of Biopharmaceutical Statistics 2006; 16: 657-677.
16. Stewart WH, Ruberg S. Detecting dose-response with contrasts. Statistics in Medicine 2000; 19: 913-921.
17. Tamhane AC, Hochberg Y, Dunnett CW. Multiple test procedures for dose finding. Biometrics 1997; 52: 21-37.
18. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine 2009; 28: 586-604.
19. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 41: 295-301.
20. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005; 61: 738-748.
21. Dragalin V, Bornkamp B, Bretz F, Miller F, Padmanabhan SK, Patel N, Perevozskaya I, Pinheiro J, Smith JR. A simulation study to compare new adaptive dose-ranging designs. Statistics in Biopharmaceutical Research 2010; 2: 487-512.
22. Dragalin V, Hsuan F, Padmanabhan SK. Adaptive designs for dose-finding studies based on the sigmoid emax model. Journal of Biopharmaceutical Statistics 2007; 17: 1051-1070.
23. Jones B, Layton G, Richardson H, Thomas N. Model-based Bayesian adaptive dose-finding designs for a Phase II trial. Statistics in Biopharmaceutical Research 2011; 3: 276-287.
24. Bornkamp B, Bretz F, Dette H, Pinheiro JC. Response-adaptive dose-finding under model uncertainty. Annals of Applied Statistics 2011; 5: 1611-1631.
25. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biometrical Journal 2008; 50: 346-363.
26. Bornkamp B, Pinheiro J, Bretz F. DoseFinding: planning and analyzing dose finding experiments R package, http://www.cran.r-project.org/web/packages/DoseFinding/.
27. Bornkamp B, Pinheiro JC, Bretz F. MCPMod: An R package for the design and analysis of dose-finding studies. Journal of Statistical Software 2009; 29(7):1-23.
28. Pinheiro JC, Bornkamp B, Bretz F. Design and analysis of dose finding studies combining multiple comparisons and modeling procedures. Journal of Biopharmaceutical Statistics 2006; 16: 639-656.
29. Genz A, Bretz F. Computation of Multivariate Normal and t Probabilities. Springer: Berlin, 2009.
30. Buckland ST, Burnham KP, Augustin NH. Model selection an integral part of inference. Biometrics 1997; 53: 603-618.
31. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Vol. I, Statistical Laboratory of the University of California, Berkeley, 1967; 221-233.
32. Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of Longitudinal Data. Oxford University Press: Oxford, 1994.
33. Dobson AJ. An Introduction to Generalized Linear Models. Chapman and Hall: Boca Raton, 2002.
34. Peddada SD, Haseman JK. Analysis of nonlinear regression models: a cautionary note. Dose-Response 2005; 3: 342-352.
35. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, Carroll RJ. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004; 5: 445-464.
36. EMA. Guideline on missing data in confirmatory clinical trials, 2011.
37. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clinical Pharmacology and Therapeutics 2012; 91: 550-554.
38. Akacha M, Benda N. The impact of dropouts on the analysis of dose-finding studies with recurrent event data. Statistics in Medicine 2010; 29: 1635-1646.
39. Ahrens H, Läuter J. Mehrdimensionale Varianzanalyse. Akademie-Verlag: Berlin, 1981.
40. Biesheuvel E, Hothorn LA. Many-to-one comparisons in stratified designs. Biometrical Journal 2002; 44:101-116.